SL1009 (sodium dichloroacetate)

Name: SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: Access and distribution
Published: 2026-09-14T15:39:06-04:00

Pyruvate dehydrogenase complex deficiency

Manufacturer: Saol Therapeutics
Regulatory submission: NDA resubmitted June 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Access and distribution

3 evidence topics · 2 sources

Expanded access: NCT06931262

“The patient is not eligible to participate in a clinical trial.” (opens the source at this quote in a new tab)
“The patient’s licensed physician (“physician”) submits an unsolicited request for expanded access.” (opens the source at this quote in a new tab)

Expanded-access request responsibility

“Only a qualified, licensed, treating physician may submit a request for expanded access to DCA for PDCD.” (opens the source at this quote in a new tab)

Genetic counseling and clinical-trial access

“After speaking with a genetic counselor, families interested in learning more about the clinical research study will be connected with a trial site.” (opens the source at this quote in a new tab)